Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks. In this ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

2025 Adjusted Tax Rate Forecast: 16% to 17%. Abbott Laboratories (NYSE:ABT) achieved a 9.5% sales growth excluding COVID testing, demonstrating strong performance across its business segments.